Predicting chemoresponsiveness in epithelial ovarian cancer patients using circulating small extracellular vesicle-derived plasma gelsolin

被引:0
作者
Emma Gerber
Meshach Asare-Werehene
Arkadiy Reunov
Dylan Burger
Tien Le
Euridice Carmona
Anne-Marie Mes-Masson
Benjamin K. Tsang
机构
[1] Ottawa Hospital Research Institute,Chronic Disease Program
[2] The Ottawa Hospital,Department of Cellular and Molecular Medicine, Faculty of Medicine
[3] University of Ottawa,Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, Faculty of Medicine
[4] University of Ottawa,Centre for Infection, Immunity, and Inflammation, Interdisciplinary School of Health Sciences
[5] University of Ottawa,Department of Biology
[6] St. Francis Xavier University,Clinical Epidemiology Program
[7] Ottawa Hospital Research Institute,Département de Médecine
[8] The Ottawa Hospital,undefined
[9] Centre de Recherche du CHUM Et Institut du Cancer de Montréal,undefined
[10] Université de Montréal,undefined
来源
Journal of Ovarian Research | / 16卷
关键词
Epithelial ovarian cancer; Chemoresistance; Biomarkers; Plasma gelsolin; Small extracellular vesicles; CA125; Prognosis;
D O I
暂无
中图分类号
学科分类号
摘要
引用
收藏
相关论文
共 180 条
[1]  
Piechocki M(2022)Trends in Incidence and Mortality of Gynecological and Breast Cancers in Poland (1980–2018) Clin Epidemiol 24 95-114
[2]  
Koziołek W(2019)Ovarian cancer: Current status and strategies for improving therapeutic outcomes Cancer Med 8 7018-7031
[3]  
Sroka D(2014)“Platinum resistant” ovarian cancer: What is it, who to treat and how to measure benefit? Gynecol Oncol 133 624-631
[4]  
Matrejek A(2020)CA125 and Ovarian Cancer: A Comprehensive Review Cancers (Basel) 12 3730-1524
[5]  
Miziołek P(2014)Prediction of tumour response induced by chemotherapy using modelling of CA-125 kinetics in recurrent ovarian cancer patients Br J Cancer 110 1517-1403
[6]  
Saiuk N(2009)CA-125 change following chemotherapy in prediction of treatment outcome among advanced mucinous and clear cell epithelial ovarian cancers: a gynecologic oncology group study Cancer 115 1395-79
[7]  
Chandra A(2008)National academy of clinical biochemistry laboratory medicine practice guidelines for use of tumor markers in testicular, prostate, colorectal, breast, and ovarian cancers Clin Chem 54 e11-2374
[8]  
Pius C(2018)Exosomes in cancer development and clinical applications Cancer Sci 109 2364-303
[9]  
Nabeel M(2019)Exosomes: biogenesis, biologic function and clinical potential Cell Biosci 9 19-12
[10]  
Nair M(2017)Exosomal DNMT1 mediates cisplatin resistance in ovarian cancer Cell Biochem Funct 35 296-1616